Search

Displaying results 3131 - 3140 of 8412 in total
  1. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

    Synonyms: 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea, N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  2. Drug

    Passiflora incarnata flower

    go.drugbank.com/drugs/DB13974
    Approved

    Mixtures: Dormiphen Au Naturel
  3. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate].

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  4. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between … [A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  5. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

  6. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration … A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim alfa can

  7. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. … ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.

  8. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  9. Drug

    Temazepam

    go.drugbank.com/drugs/DB00231
    Approved

    Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  10. Drug

    Colestilan chloride

    go.drugbank.com/drugs/DB11634
    ApprovedWithdrawn

    Colestilan is an ingredient in the EMA-withdrawn product BindRen.